^
Association details:
| Biomarker: | DLL3 positive |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | tarlatamab (AMG 757) (CD3 agonist, DLL3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
OA12.05 - Phase 1 Updated Exploration and First Expansion Data for DLL3-targeted T-cell Engager Tarlatamab in Small Cell Lung Cance
Published date:
07/12/2022
Excerpt:
DLL3 was positive by IHC (≥1%) in 96% (93/97) of available samples…Tarlatamab has an expected and manageable safety profile and delivers promising efficacy with excellent response durability amongst confirmed responders in this heavily pretreated SCLC population.
